Stroma Biosciences co-founders have been accepted as the cover story in Science Translational Medicine for their work on the tumour microenvironment. The research found that treating the normal cells near to the cancer cells with small molecule inhibitors significantly improved the effects of a broad range of chemotherapies
https://www.science.org/doi/10.1126/scitranslmed.aax9340
Stroma Biosciences has made the #21toWatch Companies Longlist
Stroma Biosciences is delighted to announce that it has made the #21toWatch Companies longlist. The highly respected annual #21toWatch campaign and awards programme showcases the people, companies and ‘things’ that are setting the standards of innovation and...